Iterum Therapeutics(US:ITRM) Newsfilterยท2024-08-07 20:30Company Overview - Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on developing next-generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings [3] - The company is advancing its first compound, sulopenem, which is a novel penem anti-infective compound with both oral and IV formulations [3] - Sulopenem has shown potent in vitro activity against a wide variety of gram-negative, gram-positive, and anaerobic bacteria resistant to other antibiotics [3] Financial Results Announcement - The company will release its second quarter 2024 financial results before the U.S. financial markets open on August 14, 2024 [1] - Management will host a conference call at 8:30 a.m. ET on the same day to discuss the financial results and provide a business update [1] Regulatory Progress - Iterum Therapeutics has submitted a New Drug Application (NDA) for oral sulopenem for the treatment of uncomplicated urinary tract infections in adult women, which has been accepted for review by the U.S. Food and Drug Administration [3] - The company has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications [3]